Latent AMR

Latent AMR refers to antimicrobial resistance that is present, emerging, or insufficiently detected within people, animals, food systems, and the environment. Its significance extends beyond clinically confirmed infections because resistant organisms and resistance genes can circulate silently before detection, treatment failure, or outbreak recognition. The market and policy context therefore spans surveillance, diagnostics, antimicrobial stewardship, infection prevention, pharmaceutical development, animal health, wastewater monitoring, and public-health coordination.

AMR management is shifting from a primarily hospital-centered issue toward a One Health model that connects human health, veterinary practice, agriculture, food production, and environmental monitoring. Global guidance from the World Health Organization, the World Organisation for Animal Health, the Food and Agriculture Organization, and the United Nations Environment Programme emphasizes coordinated surveillance and responsible antimicrobial use across these domains. The practical transformation is toward earlier detection, better prescribing evidence, stronger laboratory networks, infection prevention, and accountability for antimicrobial use in health and food systems.

Artificial intelligence can support latent-AMR management by identifying resistance patterns in laboratory, genomic, prescribing, and epidemiological data; prioritizing samples for testing; and helping clinicians interpret susceptibility results. Machine-learning tools may also assist antimicrobial discovery, molecular design, outbreak linkage, and wastewater signal analysis. Their value depends on representative datasets, interoperable systems, transparent validation, cybersecurity, and human oversight. Bias from uneven laboratory coverage or incomplete reporting can produce unsafe recommendations, so AI should augment-not replace-microbiologists, infectious-disease specialists, pharmacists, and public-health authorities.

North America has comparatively strong laboratory, genomic, and stewardship infrastructure, while still facing persistent resistance in healthcare and community settings. Europe benefits from coordinated surveillance and regulatory collaboration, although patterns differ across countries. Asia-Pacific combines advanced systems in some economies with large and diverse healthcare and agricultural environments that complicate harmonized monitoring. Latin America continues to strengthen laboratory and stewardship networks amid variable access and reporting capacity. The Middle East requires sustained infection prevention, cross-border coordination, and antimicrobial-use oversight, particularly across complex care and mobility settings. Africa faces significant diagnostic, laboratory, and access constraints, making integrated surveillance, workforce development, and affordable quality-assured testing central priorities.

ASEAN cooperation can improve cross-border surveillance, laboratory standards, and coordinated action across highly connected health and food systems. BRICS members bring substantial scientific, manufacturing, agricultural, and public-health capabilities, but benefit from stronger data comparability and shared stewardship practices. The European Union has a framework for coordinated surveillance, regulation, and One Health action. G7 countries can support financing, research collaboration, diagnostic access, and global standards. GCC members can reinforce infection prevention, hospital stewardship, and regional information sharing. NATO members can strengthen preparedness, interoperable medical planning, and protection of health systems against resistant infections during emergencies.

Australia combines strong public-health institutions with a need for continued rural, remote, agricultural, and environmental surveillance. Brazil and Mexico must expand equitable diagnostics and integrate human, animal, and environmental monitoring across large and diverse territories. Canada and the United States continue to emphasize stewardship, surveillance, laboratory capacity, and infection prevention. China and India require broad, coordinated approaches spanning hospitals, communities, manufacturing, food systems, and environmental pathways. France, Germany, Italy, Spain, and the United Kingdom have established surveillance and stewardship capabilities but must address persistent resistant pathogens, healthcare variation, and implementation consistency. Japan and South Korea can build on advanced clinical and laboratory systems while maintaining vigilance over aging populations, healthcare-associated transmission, and appropriate prescribing. Russia’s response depends on reliable surveillance, laboratory strengthening, stewardship, and transparent collaboration across health sectors.

Industry and health-system leaders should establish measurable One Health governance, connect clinical and environmental data, and expand rapid susceptibility testing where treatment decisions are time-sensitive. They should reinforce antimicrobial stewardship through prescribing feedback, pharmacy controls, diagnostic guidance, and continuous professional education. Procurement should favor quality-assured diagnostics, infection-prevention supplies, and products that support responsible antimicrobial use. Organizations should validate AI tools on local data, document model limitations, and retain expert review. Partnerships with laboratories, regulators, veterinary services, food producers, wastewater authorities, and academic institutions can close surveillance gaps and improve response speed.

This executive summary is based on a structured review of authoritative public-health and scientific evidence, including guidance and surveillance materials from recognized international organizations, national agencies, peer-reviewed research, and established One Health frameworks. Evidence was interpreted qualitatively across human, animal, food, and environmental dimensions, with attention to surveillance maturity, diagnostic access, stewardship, infection prevention, data interoperability, and policy implementation. Regional, group, and country observations were integrated only where they reflect documented system characteristics or widely recognized public-health priorities. No market estimates, forecasts, market shares, or company-specific claims were used.

Latent AMR is best addressed before resistance becomes a visible clinical crisis. The most durable response combines routine and targeted surveillance, accessible diagnostics, disciplined antimicrobial use, rigorous infection prevention, and coordinated action across human, animal, food, and environmental systems. Regional and national differences make adaptable implementation essential, while AI can improve speed and pattern recognition when governed responsibly. Leaders that invest in interoperable evidence, skilled workforces, and cross-sector accountability will be better positioned to detect hidden resistance and reduce preventable treatment failure.